Portfoliotracker

Cereno Scientific AB (publ)

CRNO-B.ST · STOCKHOLM · Healthcare Drug Manufacturers - Specialty & Generic 0/100 E

0,135 SEK
▼ −0,091 (−40,30 %)
Closed
Price as of 17. 11. 17:29, fetched 17. 11. 17:39
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap90,2 mil. SEK P/E– Forward P/E-1,1 P/S– P/B0,5 EV/EBITDA– Dividend yield– FCF yield-184,33 % EPS-0,41 SEK Net margin0,0 % Return on equity-61,9 % Beta-0,23 Debt / equity0,76
52-week range 0,25 to 8,92
3-month average volume3,8 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.

Employees
10
Country
Sweden
Data since
22. 6. 2016

Explore further

Similar companies SANION.STOVZON.ST

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account